Oncology Institute (NASDAQ: TOI) awards 30,120 RSUs to director

Rhea-AI Filing Summary

Pacala Mark L reported acquisition or exercise transactions in this Form 4 filing.

Oncology Institute, Inc. director Mark L. Pacala received an equity award of 30,120 restricted stock units (RSUs), each settling into one share of common stock. The RSUs vest in full at the company’s 2027 annual meeting of stockholders, subject to his continued service, bringing his direct holdings to 286,881 shares.

Insider Trade Summary

Net Buyer: 30,120 shares

Net Buy 1 txn

Insider Pacala Mark L

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	30,120	$0.00	$0.00

Holdings After Transaction: Common Stock — 286,881 shares (Direct)

Footnotes (1)

1. F1. Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of the Issuer's common stock upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on the vesting date.

Key Figures

RSUs granted: 30,120 shares Per-share grant price: $0.0000 per share Shares following grant: 286,881 shares +1 more

4 metrics

RSUs granted 30,120 shares Grant of restricted stock units to director Mark L. Pacala

Per-share grant price $0.0000 per share Reported transaction price for the RSU award

Shares following grant 286,881 shares Total direct common stock holdings after the RSU grant

Vesting event 2027 annual meeting of stockholders RSUs vest in full at the 2027 annual meeting, subject to continued service

Key Terms

restricted stock units (RSUs), vest in full, annual meeting of stockholders

3 terms

restricted stock units (RSUs) financial

"Represents grant of restricted stock units (RSUs), each of which entitle..."

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

vest in full financial

"The RSUs vest in full on the date of the Issuer's 2027 annual..."

annual meeting of stockholders financial

"on the date of the Issuer's 2027 annual meeting of stockholders, subject..."

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/29/2026 - 06:53 PM Accepted by SEC EDGAR 07/29/2026 - 06:53 PM Learn about SEC filing dates

FAQ

What insider transaction did Oncology Institute (TOI) director Mark L. Pacala report?

Mark L. Pacala reported an equity award of 30,120 restricted stock units (RSUs) of Oncology Institute, Inc. Each RSU converts into one share of common stock, increasing his direct holdings to 286,881 shares after the grant.

How many Oncology Institute (TOI) RSUs were granted to Mark L. Pacala?

Mark L. Pacala was granted 30,120 RSUs of Oncology Institute, Inc. According to the filing, each RSU entitles him to receive one share of common stock upon settlement, subject to the vesting conditions described.

When do the RSUs granted to Oncology Institute (TOI) director Mark L. Pacala vest?

The RSUs vest in full at Oncology Institute’s 2027 annual meeting of stockholders. Vesting is conditioned on Mark L. Pacala’s continued service with the company through that meeting date, as stated in the footnote.

What is Mark L. Pacala’s total Oncology Institute (TOI) share ownership after this RSU grant?

Following the RSU grant, Mark L. Pacala directly owns 286,881 shares of Oncology Institute common stock. This total includes the effect of the 30,120 RSUs reported in the Form 4 transaction summary.

Did Mark L. Pacala buy Oncology Institute (TOI) shares on the open market in this filing?

No. The Form 4 shows a grant of 30,120 RSUs at a reported price of $0.0000 per share. This indicates an equity award rather than an open-market purchase transaction for cash consideration.

What kind of security was involved in Mark L. Pacala’s Oncology Institute (TOI) Form 4?

The transaction involved restricted stock units (RSUs) linked to Oncology Institute common stock. Each RSU entitles Mark L. Pacala to receive one share of the company’s common stock when the units settle after vesting.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pacala Mark L

(Last) (First) (Middle)

C/O THE ONCOLOGY INSTITUTE INC.

18000 STUDEBAKER RD, SUITE 800

(Street)

CERRITOS CALIFORNIA 90703

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oncology Institute, Inc. [ TOI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/27/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/27/2026		A(1)		30,120	A	$0.00	286,881	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of the Issuer's common stock upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on the vesting date.

	/s/ Mark Hueppelsheuser, Attorney-in-Fact for Mark L. Pacala	07/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)